Patents by Inventor Steven Witt Dodd

Steven Witt Dodd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING REGIMENS FOR SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS
    Publication number: 20250049934
    Abstract: The instant disclosure provides selective Treg stimulator compositions, including RUR20kD-IL-2 and related compositions, and rezpegaldesleukin, and formulations and dosing regimens for methods of using these compositions, for example, for treating autoimmune diseases, including atopic dermatitis.
    Type: Application
    Filed: December 14, 2022
    Publication date: February 13, 2025
    Inventors: Ali Ashrafzadeh, Steven Witt Dodd, Kimberley Anne Jackson, Stacey Masaaki Kaneshiro, Paul Alan Klekotka, Brian Leslie Kotzin, Carsten Schmitz, Jonathan Zalevsky
  • Chronic treatment regimen using glucagon-like insulinotropic peptides
    Patent number: 7989585
    Abstract: The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: August 2, 2011
    Assignee: Eli Lilly and Company
    Inventors: Steven Witt Dodd, Kenneth Francis Mace, Michael Ernst Trautmann
  • CHRONIC TREATMENT REGIMEN USING GLUCAGON-LIKE INSULINOTROPIC PEPTIDES
    Publication number: 20090186813
    Abstract: The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range.
    Type: Application
    Filed: August 10, 2007
    Publication date: July 23, 2009
    Inventors: Steven Witt Dodd, Kenneth Francis Mace, Michael Ernst Trautmann
  • Chronic treatment regimen using glucagon-like insulinotropic peptides
    Patent number: 7259233
    Abstract: The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: August 21, 2007
    Assignee: Eli Lilly and Company
    Inventors: Steven Witt Dodd, Kenneth Francis Mace, Michael Ernst Trautmann
  • Chronic treatment regimen using glucagon-like insulinotropic peptides
    Publication number: 20040053819
    Abstract: The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range.
    Type: Application
    Filed: June 10, 2003
    Publication date: March 18, 2004
    Inventors: Steven Witt Dodd, Kenneth Francis Mace, Michael Ernst Trautmann